ABSTRACT
Epidemiología de la Vulvovaginitis Micótica y el uso de Agentes Antifungales Ante la Sospecha de Vulvovaginitis Micótica, y sus Implicaciones en la Práctica Clínica

PATIENTS AND METHODS
A prospective study was conducted over a six-month period at the UHWI, with the approval of the University Hospital of the West Indies/University of the West Indies ethical committee. Written consent was received from all participants enrolled in the study. All patients attending the Obstetrics and Gynaecology Outpatient Clinics with a clinical diagnosis of vulvovaginitis were enrolled in the study. A clinical diagnosis is commonly based on the presence of one or more of the following symptoms and/or signs (6, 7): vulval itching, vaginal discharge, dyspareunia or dysuria, localized or generalized erythema of the vulva, vagina, labia majora and perineum, fissuring of the vagina and/or oedema, white and cheese-like vaginal discharge, watery or purulent discharge, odourless discharge and presence of satellite lesions.
The criteria for laboratory diagnosis of mycotic vulvovaginitis were based on the following (7, 8) : microscopic findings of hyphae and budding yeast, a positive germ tube test for Candida albicans, a positive yeast culture and a positive biochemical yeast assimilation test using the Remel RapID Yeast Plus System ® . A definitive diagnosis of mycotic vulvovaginitis was made when both the clinical vulvovaginitis and laboratory criteria were satisfied.
For the study, the required specimens were a high vaginal and an endocervical specimen collected using a separate dry cotton tip swab turned through 360 degrees. Each swab was then placed in a separate bottle of Stuart's transport medium and transported to the laboratory at room temperature within 24 hours of collection. The laboratory investigations were performed in the Microbiology Department at the The University of the West Indies (UWI) according to recommended guidelines (8) .
Gram stains and potassium hydroxide preparations were performed directly on specimens for observation of yeast and hyphae. Cultures for fungi were done using Saborauds Dextrose and Mycobiotic Agar media. The inoculated media were incubated at 30°C and observed every two to three days for fungal growth. All yeast isolates were examined for the production of pseudohyphae by the Germ Tube test. Speciation of yeast was done using the commercially prepared assay for assimilation, The Remel RapID Yeast Plus System ® .
RESULTS
A total of 422 patients were enrolled in the study. Observed ages ranged from 15 to 50 years, with the majority of cases occurring between the ages 20 to 35 years. Specimens were received from 354 (84%) of the 422 enrolled cases. Yeast isolates were confirmed in 134 (32%) cases. Frequencies of yeast isolated included, 104 (78%) C albicans, 14(10%) C tropicalis, 7 (5%) Prototheca wickerhamii (P wickerhamii), 6 (4%) C glabrata, 2 (2%) Cryptococcus albidus, (C albidus) and 1(1%) C lusitaniae. Of the 134 positive cases, treatment prescribed was: antifungals : 100 (75%); antibiotics : 23 (17%) and no treatment : 11 (8%).
Azole antifungals were used in 95 (71%) cases, polyenes in a single (0.7%) case and cicloproxolamine in 4 (3%) cases. Of the 95 cases treated with azoles, imidazoles were used in 87 (92%) cases and the triazoles in 11 (12%). A negative yeast culture was obtained in 220 (62%) of the cases of which 182 (83%) were treated, 119 (54%) with antifungal and 63 (29%) with antibiotics whilst 38 (17%) received no treatment. Empirical treatment in yeast culture positive cases are shown in the Table. Of note, 56% of cases of C albicans were treated with imidazoles (clotrimazole-Mycelex, Lotrim, Gyne-Lotrim, Clotriderm, Myoril and Canesten and ketokonazole-Nizoral) 4%, with triazoles (fluconazole-Diflucan and itraconazole-Sporonox); combined imidazoles and triazoles 3%; imidazoles and antibiotics 7%; triazoles and antibiotics 1%; cicloprox olamine (Batrafen) 2%; polyenes (Nystatin) 1% and antibiotics alone 16%.
DISCUSSION
In this study, we observed that C albicans (78%) was the most frequent aetiologic agent associated with mycotic vulvovaginitis, with non-albicans species accounting for 15%. This finding is in keeping with other studies worldwide, in which the frequency of C albicans varies between 45% to 90%. Among the non-albicans species, C tropicalis (10%) was more frequently isolated than C glabrata (4%). C lusitaniae, uncommonly associated with vulvovaginitis, was isolated in one (1%) case. Other unusual findings of this study include the isolation of the opportunistic pathogens C albidus and P wickerhamii, not commonly isolated in vulvovaginitis.
The fact that C tropicalis was more frequently isolated than C glabrata has been observed in other Latin American countries, but is reversed in the United States of America and Canada, where C glabrata occurs more frequently than C tropicalis (1, 9) .
Results of this study showed that the azole antifungals were prescribed most frequently in patients with Candida vaginitis, with the older imidazoles (ketoconazole, clotrimazole) being used more commonly than the triazoles (itraconazole and fluconazole). Of concern is the wide variety of agents used in the treatment of the most common isolate, C albicans. It is well known that Candida specie vary in their susceptibility to antifungal agents, with secondary or acquired resistance of C albicans and shifts in flora away from C albicans towards the less susceptible non-albicans species being associated with multiple courses of azole therapy. The resistance of Candida species to the older azoles, such as ketoconazole, occurs in a pattern that appears to parallel resistance to itraconazole. Currently, the most significant form of azole resistance is that seen between Candida and fluconazole, with estimated frequencies varying up to 23% (7, 9,) . Oral fluconazole represents the only systemic therapy that the Centers for Disease Control and Prevention (CDC) recommends for the management of uncomplicated vulvovaginal candiasis. Vaginal triazole resistant C albicans isolates are considered to be rare, with reported cases being associated with refractory vulvovaginal candidiasis and a history of azole self-medication. A Belgian hospital-based study of 612 women attending obstetrics-gynaecology outpatient clinics found the prevalence of fluconazole-resistant C albicans isolates to be 23%. The authors commented that when compared with intravaginal azole antifungals, oral azole therapy is considered to achieve comparable or marginally higher therapeutic cure rates for vulvovaginal candidiasis. They also advised that the appropriateness of prescribing the triazoles for vulvovaginal candidiasis should be within the recommended guidelines with particular attention to the dosage and duration of the drug and the potential for drug resistance (7) . Cross-resistance to other azole antifungal agents is common but not universal and is not associated with cross-resistance to polyene antibiotics, such as amphotericin B and nystatin (9) . Unlike the azole drugs that exert their effect by inhibition of fungal cytochrome P450 enzymes, the polyene antifungals act by binding to ergosterol, in the fungal cell membrane. Resistance to the polyene antifungals remains an uncommon event among Candida isolates. The polyenes still have reliable activity against most of the Candida species, except C lusitaniae, which is often intrinsically resistant. In addition, reduced susceptibility appears common among isolates of C glabrata (9, 10) . The susceptibility of Candida species to Cicloproxolamine has been shown to be similar to that of the imidazoles (11) .
The emergence of non-albicans Candida species is also clearly a concern. Prototheca, a genus of achlorophyllic algae, is a rare cause of opportunistic infections in humans. Polyene antifungals remain the most effective drugs for eradicating Prototheca infections. Azole antifungals may also be used with more localized infections, itraconazole being the most effective drug of this class (12) . Of the three Prototheca isolates (66.6%) two were appropriately empirically treated, one with an imidazole, and the other with a triazole. The other was in the group inappropriately empirically treated with antibiotics.
Recently, the number of reports of the isolation of nonneoformans Cryptococcus species from clinical specimens and opportunistic infection by this species has been increasing. This basidiomycetous yeast is known to be sensitive to the polyene antifungals and to vary in resistance to azoles such as fluconazole and itraconazole. In view of this possible resistance, the use of polyene antifungals for the treatment of C albidus associated vaginitis in this study would have been the more appropriate drug of choice (13) .
Antifungal therapy was inappropriately prescribed in 54% of culture negative cases. Such unnecessary use of anti- fungal therapy contributes to the development of antifungal resistance and the emergence of infections associated with non-C albicans yeast and other opportunistic fungi. Mycotic vulvovaginitis, which is largely treated empirically, presents both a diagnostic and therapeutic challenge. Inappropriate management may result in the progression to complicated vaginitis, enhance the development of antifungal resistance or the emergence of uncommon species. In this context, the role of the laboratory in the identification and speciation of aetiological pathogens is essential to the avoidance of pitfalls of empiricism and the identification of developing trends in species distribution.
In summary, this study has demonstrated the need to emphasize the importance of accurate diagnosis and appropriate use of antimycotic agents in patients presenting with the common complaint of vulvovaginitis/vaginal discharge. There is also need for further study to identify resistance patterns of yeast.
